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Abstract
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INTRODUCTION—Deleterious mutations in the BRCA1/BRCA2 genes elevate lifetime risk of
breast and ovarian cancer. Each child of a mutation-positive parent has a 50% chance of inheriting
it. Pre-implantation genetic diagnosis (PGD) permits prospective parents to avoid transmitting a
BRCA1/2 mutation to a child, introducing predictability into a process historically defined by
chance. This investigation explored how BRCA1/2 mutation carriers understand genetic
inheritance and consider a child’s inheritance of a BRCA1/2 mutation, given the opportunities that
exist to pursue PGD.
METHOD—39 female and male BRCA1/2 mutation carriers of reproductive age were recruited
from urban cancer and reproductive medical centers. Participants completed a standardized
educational presentation on PGD and prenatal diagnosis, with pre- and post-test assessments. An
interdisciplinary team of qualitative researchers analyzed data using grounded theory techniques.
FINDINGS—Participants expressed the belief that reproduction yields children with unique
genetic strengths and challenges, including the BRCA1/2 mutation, family traits for which
predictive tests do not exist, and hypothetical genetic risks. Participants expressed preference for
biologically-related children, yet stated their genetically ‘well’ partner’s lineage would be marred
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through reproductive merger, requiring the well partner to assume the burden of the BRCA1/2
mutation via their children. Participants expressed diverse views of genetically ‘well’ partners’
participation in family planning and risk management decisions.
DISCUSSION—Pressure to use reprogenetic technology may grow as genetic susceptibility
testing becomes more widely available. Work with individuals and couples across the disease
spectrum must be attuned to they ways beliefs about genetic inheritance play into reproductive
decision making.
Keywords
BRCA mutation; pre-implantation genetic diagnosis; human reproduction; couples; genetic
inheritance

INTRODUCTION
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Inheriting a deleterious mutation in the BRCA1 or BRCA2 genes dramatically increases a
woman’s lifetime risk of developing breast and ovarian cancer. By age 70, an estimated
60-70% of BRCA1 mutation carriers and 45-55% of BRCA2 mutation will develop breast
cancer, and 40% of BRCA1 mutation carriers and 20% of BRCA2 mutation carriers will
develop ovarian cancer (Clark & Domchek, 2011). Much of this risk occurs before age 50.
Either biological parent can carry a BRCA1/2 mutation and pass it to a child, and each child
of a mutation carrier has a 50/50 chance of inheriting it.

NIH-PA Author Manuscript

In the last decade, cutting edge screening and preventive options have provided BRCA1/2
mutation carriers with a number of risk management options. Even more recently, advances
in genetically enhanced assisted reproductive technologies, also known as repro-genetic
technology, have pushed the possibility of screening and prevention into the realm of
reproduction. A number of reproductive options exist that prevent the birth of a child who
carries a BRCA1/2 mutation, including forgoing conventional conception for either adoption
or gamete donation. Pre-implantation genetic diagnosis (PGD) is an emerging reproductive
option to avoid transmitting a BRCA1/2 mutation to the next generation (Meister, Finck,
Stobel-Richter, et al., 2005; Quinn, Tuya, Murphy, et al., 2012; Sagi, Weinberg, Eilat, et al.,
2009; Vadaparampil, Quinn, Knapp, et al., 2009). PGD requires in vitro fertilization
treatments with an additional genetic testing stage to identify and transfer to the uterus
embryos that do not have a deleterious mutation carried by a biologically related parent.
Prenatal diagnosis requires that a pregnant woman undergo chorionic villus sampling (CVS)
or amniocentesis followed by consideration of selective abortion. Although technically
feasible, this is rarely utilized by BRCA1/2 mutation carriers (Offit, Sagi & Hurley, 2006).

LITERATURE REVIEW
Genetic material from each biological parent is randomly sorted into egg and sperm prior to
conception to promote variation. At conception, each child receives a full complement of
genes from each parent, including a unique constellation of strengths, vulnerabilities and
traits.For would-be parents interested in and able to become biological parents, the mixing
of ones’ genetic material with that of another in wholly unique ways can be very exciting.
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Seeing pieces of oneself in another is a very special part of parenthood, particularly with
respect to those traits viewed, either personally or socially, as strengths. However, concern
about genetic predisposition to hereditary breast and ovarian cancer and other genetic
conditions, and the random nature of genetic inheritance, may complicate these feelings.
Prospective parents may “have to do a calculus of how good are the qualities they believe
they can pass on in their genes, against how bad are the qualities of the disease they may
also pass on” (Katz Rothman, 1998, p. 126).
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Increasing availability of PGD to identify gene mutations for adult onset conditions such as
hereditary breast and ovarian cancer (Offit, Sagi & Hurley, 2006) and its potential use for
non-medical conditions may force would-be parents to examine what they bring to the
reproductive table in both concrete (‘what I have to pass on’/phenotype) and abstract terms
(‘what my child could inherit from me’/family history). The National Comprehensive
Cancer Network (NCCN, 2011) recommends discussion of family planning wishes and
introduction of assisted reproductive technologies, including PGD, during cancer risk
counseling. The introduction of PGD during genetic testing may invite those involved in
family planning to consider a future child’s inheritance of a much broader range of inherited
traits and conditions, medical and non-medical, against which the dangers of a BRCA1/2
gene mutation are measured. The availability of repro-genetic technologies may push
would-be parents to consider action (Dommering, van den Heuvel, Moll, et al, 2010) as they
anticipate those traits or conditions they hope their children will not inherit, traits they wish
to select out.
Perspectives on PGD in Social and Family Life
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Public perception about what PGD permits (eg: designer babies) focuses on what traits could
be selected in (eg: eye color, intellectual prowess). Preference for specific genetic profiles or
characteristics over others is not exclusive to the age of genetic discovery. Concern that
PGD is the first misstep down a ‘slippery slope’ is shaped by the dark history of sterilization
and eugenics as a mechanism of social enhancement and control (Franklin & Roberts, 2006).
The characterization of PGD as a tool for made-to-order babies may deter would-be parents
interested in reducing a child’s risk of pain and suffering. Further, public discourse about
PGD is shaped by the more recent concern over the ethically controversial application of
repro-genetic technologies to birth ‘savior siblings’ who can provide stem-cell-rich cord
blood to an older child with a known genetic disease, or for sex selection. PGD may also be
coupled to anti-abortion sentiment as viable, yet affected embryos created through the
techniques of in vitro fertilization are discarded after being deemed ‘unfit.’ Yet, public
discourse regarding PGD is shaped by a public with limited exposure to the physical and
emotional rigors of in vitro fertilization, or the challenges that lead to consideration of PGD
(Franklin & Roberts, 2006)
BRCA1/2 mutation carriers’ perspectives on the ‘slippery slope’ (Quinn, Vadarampil,
Wilson et al., 2009) may exist in tension with each individual’s experience of an illness that
‘runs in the family’, as well as experiences of care giving and loss (Brouwer-DudokdeWit,
Savenije, Zoeteweij, et al., 2002; Chilibeck, Lock & Sehdev, 2011; Hoskins, Roy & Greene,
2012; Sobel & Cowan, 2003). For prospective parents, justification for using PGD may be
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couched in attitudes towards and understandings of technology (Rodin & Collins, 1991), in
reproductive hopes and challenges, and in family aspirations (Finkler, Skrzynia & Evans,
2011). Like many BRCA1/2-related risk management decisions (Hallowell, Foster, Eeles,
Ardern-Jones, & Watson, 2004), reproductive decisions are rarely made in social isolation.
For couples, the family history of each partner may diverge with respect to experiences and
interpretations of illness and loss. BRCA1/2 mutation-positive individuals may have distinct
disease related beliefs and concerns about passing the mutation to a child. These beliefs may
or may not dovetail with the experiences of mutation-negative partners, leading to tension in
reproductive planning (Werner-Lin & Gardner, 2009). Pressure to use repro-genetic
technologies may also emerge from a variety of other individuals invested in the health of
the future child and family, including affected and extended family members, in-laws (i.e.
future grandparents, aunts and uncles), and health care providers (Rubin, Werner-Lin, Stern,
et al. 2011).
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PGD introduces the possibility of choice into a situation historically defined by chance
(Ehrich & Williams, 2010; Franklin & Roberts, 2006), and suggests a family’s genetic line
can become unencumbered by a specific inherited disease risk for future generations
(Franklin & Roberts, 2006). Yet, PGD is an imperfect technology; it introduces additional
uncertainties for BRCA1/2 gene mutation carriers (Rubin, Werner-Lin, Stern, et al. 2011).
PGD involves medically invasive and expensive procedures, does not guarantee a successful
pregnancy or a mutation-free baby (Offit, et al., 2006) and presents a host of novel ethical
issues about selecting and discarding embryos. This study is situated in the context of a
broader investigation of BRCA1/2 mutation carriers’ attitudes about the use of, as well as the
ethical and social acceptability of, PGD and prenatal diagnosis to screen embryos and
fetuses for a BRCA1/2 mutation. The broader study sought also to elicit opinions from
BRCA1/2 mutation-positive women and men as to whether and how information about PGD
and prenatal diagnosis should be presented during genetic counseling. During discussion of
these assisted reproductive technologies, participants revealed the ways they construe
genetic inheritance, including how they consider passing on a BRCA1/2 mutation to a child
given the opportunities that exist to pursue PGD. The purpose of this paper is to report on
beliefs and values expressed by participants surrounding the process of combining disparate
genetic lines to produce children, and the ways participants negotiate the possibility of
shaping (through the use of PGD or prenatal diagnosis) the otherwise random process of
inheritance.

NIH-PA Author Manuscript

DESIGN
Sampling and Recruitment
Participants were recruited from the Clinical Genetic Service of a private, comprehensive
cancer center in New York City. Inclusion criteria required participants: (1) carried a
deleterious BRCA1/2 mutation documented by Clinical Genetics; (2) were of ‘reproductive
age’ defined as under age 43 for women and under age 50 for men; and (3) that women had
not undergone hysterectomy or risk reducing oophorectomy. Ninety-eight eligible Clinical
Genetics patients were mailed an invitation letter, followed by a phone call to assess interest
and schedule an interview. 45 of 98 prospective participants did not respond to recruitment
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efforts, and 19 declined participation upon contact. Among decliners, the majority (10) cited
inconvenience, scheduling conflicts, or being too busy. Five decliners felt that topics related
to BRCA1/2 and/or PGD were too emotionally difficult. Data from one participant was
excluded due to an active psychiatric episode that rendered her responses unreliable.
Later in the study, a second sample of patients who sought consultation for PGD to screen
embryos for a BRCA1/2 gene mutation were recruited through a Center for Reproductive
Medicine in New York City. Eligibility criteria were the same, with the exception that
mutation-negative female partners were eligible to participate. The genetic counselor at the
Center contacted 11 eligible patients by phone. Seven initially agreed to participate,
although one woman actively cycling for in vitro fertilization cancelled her scheduled
appointment citing it was “a little too much to think about right now.” Reasons for declining
participation were not recorded for other patients at the Center. Institutional review boards at
both medical institutions approved the protocol.
Procedures

NIH-PA Author Manuscript

Interviews with patients from Clinical Genetics were conducted at the hospital’s counseling
center. Interviews with patients at the Center for Reproductive Medicine were conducted
either at the Center or the patients’ home, determined by the patients’ preference. The
study’s Principal Investigator, a licensed doctoral-level clinical psychologist, or a study CoInvestigator, a licensed doctoral-level social worker, completed all interviews. Both had
prior clinical and research experience with individuals at hereditary risk for cancer.
Participants provided informed consent followed by completion of a demographic
questionnaire and assessment of prior experience with and knowledge of prenatal diagnosis
and pre-implantation genetic diagnosis.

NIH-PA Author Manuscript

The study interviewer then presented participants with a standardized educational tutorial,
developed in collaboration with a doctoral-level genetic counselor and approved by genetic
counselors on the Clinical Genetics Service, reviewing risk and inheritance patterns
associated with BRCA1/2 gene mutations, defining pre-implantation genetic diagnosis and
prenatal genetic diagnosis, and describing the procedures and associated features (e.g.,
ethical considerations, cost) for each. This assured participants shared a basic proficiency in
patterns of cancer risk and inheritance associated with BRCA1/2 gene mutations, and the
procedures, features, and risks of both PGD and prenatal diagnosis. Two versions of the
tutorial were developed to balance any “order effect” associated with the presentation of
PGD or pre-natal diagnosis. We alternated between these two presentations for each
consecutive interview. Following the educational presentation, participants completed a
brief knowledge assessment to ensure comprehension of the key points of the educational
presentation. This demonstrated that participants were able to distinguish PGD from prenatal diagnosis based on its core biomedical features.
Participants then completed an in-depth, semi-structured interview [see Table 1.] exploring
experiences of familial cancer and genetic testing, surveillance and prevention options for
BRCA1/2 mutation carriers, the impact of a BRCA1/2 mutation on family planning, and
attitudes towards the use of PGD and prenatal diagnosis. Religious and family views, and
cost were also explored. For the one couple that participated, the educational presentation
Fam Syst Health. Author manuscript; available in PMC 2014 November 13.
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was delivered together. Interviews were conducted separately with each partner first, then
together afterwards to discuss any additional information. Interviews lasted between 45 and
120 minutes. [Insert Table 1. Excerpted Interview Guide]
Data Management
All interviews were audio-recorded and transcribed verbatim by a professional transcription
service. The research team used a grounded theory approach to data management, including:
a) constructing analytic codes and categories from data, not from a priori assumptions; b)
using the iterative, “constant comparative”, method; and c) memo-writing to elaborate and
define categories, propose relationships between categories, and identify gaps in
understanding (Beeson, 1997; Charmaz, 2000; Strauss & Corbin, 1995).
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The interdisciplinary research team included disciplines of medicine, genetic counseling,
molecular biology, psychology, social work and anthropology. Two members of the
interdisciplinary data analysis team read each transcript line-by-line, and independently
created a case summary that included participant demographics, personal and family cancer
history, a sum of their responses to key study questions, and key themes that arose during
the interview. Members of the team then independently re-read transcripts to generate an
initial set of open codes and categories [using Atlas.ti software to manage and organize
data]. The team used a set of procedures derived from grounded theory to guide analysis
when a project employs multiple coders, to facilitate group discussion towards agreement on
a set of codes and categories that best represent the data. These codes and categories formed
the initial codebook. The research team met regularly throughout data collection and
analysis to revise the coding scheme to accommodate emergent themes. Discrepancies were
brought to the full team for discussion, clarification, and resolution.
The primary codebook for this arm of the study focused beliefs about family formation and
genetic inheritance, family lineage, and the processes by which prospective parents negotiate
family planning. A select group of researchers initiated axial coding procedures, which
included grouping codes into conceptually meaningful clusters and hierarchies. During this
process, grouped codes are defined and their properties and sub-codes are identified.

NIH-PA Author Manuscript

Trustworthiness—Collaboration across professional disciplines helped the research team
remain reflexive during data management and to ground findings in both the patients’ needs
and the professional mandates of health care providers. Consultation with qualitative
research experts and maintenance of a detailed audit trail [method of tracking decisions and
interpretations of data] facilitated rigorous and transparent data collection and management.
Outliers were included in analysis and examined for unique contributions to the
development of theory and practice recommendations (McPherson & Thorne, 2006).

FINDINGS
Thirty-nine interviews were conducted, with a total of 34 females and 5 males participating.
The majority where white (92%), married (76.9%), working full time (59%), and affluent
(nearly 70% reported annual incomes greater than $100,000). Just over half of the sample
had children (56.4%), and nearly 80% reported they were not finished (or not sure they were
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finished) with plans for having children. 64% report being raised Jewish, and 61.5% are
currently affiliated in some way with the Jewish faith and traditions. All participants were
BRCA1/2 mutation-positive, except one female participant who was undergoing PGD to
identify and screen out a BRCA1/2 gene mutation carried by her husband. The parameters of
the protocol prevented us from interviewing partners of mutation positive women and men
because they were not patients at these respective medical institutions. Data from the
mutation-negative wife (who was actively cycling at the Center for Reproductive Medicine
and was, thus, eligible to participate) and from the couple’s joint discussion with the
researcher was treated as a unique case and is integrated into the findings anecdotally (and is
so noted). Data from one participant was excluded due to an active psychiatric episode that
rendered her responses unreliable.

NIH-PA Author Manuscript

During discussion of attitudes about PGD, participants revealed perceptions about the
BRCA1/2 gene mutation as one piece of a comprehensive set of genetic traits and conditions
they had to offer children via either genetic inheritance or, with adopted children, through
nurturing of character. Participants discussed ways in which, through the process of
reproduction, genetic lines are combined to produce children with their own set of unique
strengths and challenges. The preference for biologically related children was strong, yet
participants stated that in creating genetically linked children, the health of their genetically
‘well’ partner’s lineage would be marred. As a result, these well partners would assume the
risk and burden of the BRCA1/2 gene mutation via their children.
“My funky genetics”: Merging genetic lines to produce children
Despite the presence of a BRCA1/2 gene mutation, the desire to bear and invest in ones’
genetic progeny was linked, for some participants, to conventional views about the purpose
of marriage. A participant stated: “I felt like marriage is about a lot of things, but one of the
things that it’s about is creating little people that are both of you and the joy of figuring out
what both of you can do” (PGD034). Yet, during discussion of family planning, participants
shared beliefs, opinions, concerns, and hopes about what could and could not be inherited by
their children. This included both desirable and undesirable genetic conditions and traits.
Consistent with findings from other studies investigating BRCA1/2 mutation carriers’
reproductive concerns (Werner-Lin, 2010), one woman said: “It’s the first thing I thought,
you know, my poor kids, that this is what I’m passing on to them” (PGD026).

NIH-PA Author Manuscript

Some participants identified the BRCA1/2 mutation as ‘defective’ or ‘funky.’ In contrast,
they described a family history without chronic and pervasive disease as indication of
‘clean’ genetic material. A woman who had recently postponed family planning due to job
loss discussed playful teasing by her husband, whose family did not have any indication of
inherited disease risk, saying:
He comes from a long line of people who live very long and have very few health
problems…he’s got the great genetics, so he’s been teasing me about I brought the
defective genes to the family pool. So it’s in a teasing kind of vein, that I’m
dragging down his perfect genetic record with my funky genetics (pgd028).
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She shares her view that, through reproduction, her ‘funky’ genetic line is merged with her
husband’s ‘clean’ line. As the genetic code of mother and father are intertwined in the child,
the well partner assumes the risk, responsibility, and burden of the BRCA1/2 mutation. Her
language indicates the perceptions that she actively participates in this merger by ‘dragging
down his perfect genetic record.’ While this participant reported the teasing as lighthearted,
she went on to say: “I felt a little bit guilty bringing this issue to their family “(PGD028).
Rather than hoping she would pass on her mutation-negative copy of the BRCA gene,
resulting in a mutation-negative child, this participant discussed the concern that she would
mar her partner’s healthy genetic line if she produced a BRCA1/2-positive child. Such an
interpretation suggests she understood the BRCA1/2 gene mutation as overriding, or
masking, the contribution of her partner’s DNA.
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Other participants also expressed guilt about bringing a BRCA1/2 mutation to a ‘clean’
genetic line and of their partner’s ‘inheritance’ of those alleles via their children. One
mother discussed the importance of her husband attending genetic counseling sessions,
saying: “One of the reasons it was helpful for him to be there is this isn’t part of his family’s
history, but now it is part of his family, right? He needs to have this information to know
about this for his own children” (PGD26). A mutation-positive male, overpowered by the
coalition between his carrier mother and his non-carrier wife, lamented that neither woman
was interested in considering PGD. He said: “The kid is just as much hers as mine. She owns
the gene as much as I do at this point” (PGD082).

NIH-PA Author Manuscript

Some participants created balance in their reproductive merger with partners by identifying
the difference between mutations that genetic testing can identify (eg: BRCA1/2) and
predispositions or family traits potentially carried by themselves or their partners for which
genetic tests are not yet available. One participant shared: “It’s just part of the cards I was
dealt. His family has depression, I have this” (PGD057). Another shared: “Cancer’s not a
particular problem for him. His family has other problems. [laughs] I guess we all have
whatever, but-yeah, there seems to be Alzheimer’s in his family.” This participant may frame
Alzheimer’s as a familial disease (although, like some hereditary cancer syndromes, familial
Alzheimer’s accounts for only about 5% of cases). This participant articulates the growing
lay perception (Emslie, Hunt & Watt, 2003), fed through findings from the Human Genome
Project, that every individual carries some genetic defect. This thinking levels the playing
field as this participant reconciles her known mutation with the possibility that her partner
also brings genetic risks to the reproductive table.
Finally, some participants cited unknown diseases or traits, ones not visible or identified in
their own or in their partner’s genetic line. These hypothetical genetic risks, such as rare
recessive traits, would confer what they believed to be greater risks than a BRCA1/2 gene
mutation.
You’re not necessarily going to develop cancer just because you carry the gene. So
if I screened out an embryo that was a carrier of the BRCA gene maybe that’s the
embryo that is actually a carrier for something else even more horrible (PGD070).
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The possibility that this prospective parent might actively, yet unknowingly, select an
embryo affected by a yet unknown genetic disease left her conflicted about PGD as she
considered the possibility of committing a ‘sin of commission’ (Baron & Ritov, 2004).
“My own kids”: Perspectives on the Genetic Link between Parent and Child
Aside from balancing one’s genetic material with that of another, participants also struggled
to reconcile the mixture of strengths and risks in their own profile.
Passing on desirable traits
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While participants used words like ‘defective’ and ‘dirty’ to describe the BRCA1/2 mutation,
many also cited traits they hoped their children would inherit. Consistent with research on
families with hereditary non-polyposis colorectal cancer (HNPCC, McAllister, 2003), some
participants coupled mental fortitude in the face of illness with inheritance of the BRCA1/2
mutation. Three participants who described their mothers using terms such as ‘storm
troopers’ (while they actively fought off cancer and maintained family routines during trying
cycles of chemotherapy) were particularly adamant about passing on their genetic material,
specifically strength of character, to their children. Other positive traits were much more
general, such as intellectual prowess, physical traits, talents, and a sense of humor or
musicality. Anecdotally, the couple interviewed that was actively undergoing PGD to screen
for a BRCA1/2 gene mutation sat together with the interviewer, and each discussed those
traits they hoped their child inherited from the other partner. They reported these were the
traits that had attracted them to each other and remained the compliment of strengths that
kept them together.
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Some participants discussed specific positive and desirable traits they had to offer a child.
Mention of these traits was generally couched in discussions of participant preferences for
biologically related children. This preference was quite common in our sample, expressed
with conviction, and consistent with findings from other recent studies (Leontini, 2010). A
participant experiencing infertility discussed her reactions when her reproductive
endocrinologist suggested she pursue donor gametes: “The possibility was that I wouldn’t
have any children, that I wouldn’t pass on any of my genes and to me that was unacceptable.
If there was any way at all that I could have my own kids I wanted to do that” (PGD034). As
she spoke, this participant conflated passing on her genes with having ‘her own’ children. A
participant discussing a meeting with her reproductive endocrinologist after her mastectomy
used similar language, saying of this conversation: “my chances were very low of having my
own baby, my own genes” (PGD091). A participant, ambivalent about becoming a parent,
said: “I can’t say that I’m really gung-ho about having kids to begin with but then certainly
the prospect of having a child with potentially a genetic mutation and have to face the things
that I face…” (PGD056). She went on to say that if she did decide to become a parent,
however, she would only be interested in using her own gametes, “I’m a very intelligent
person and my husband’s very intelligent —why wouldn’t you want to create a child with
your own genetic material?”
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Individuals with a family history of disorders that impact cognitive and social functioning
expressed the attitude that these disorders presented a more pervasive threat than a BRCA1/2
genetic mutation .In discussing her history of anxiety, one woman shared:
There are so many bigger things that I’ve dealt with in life and I can’t say it’s
because of cancer. I could say it’s because I have an anxiety problem…if I was
going to start weeding out certain things I would probably take my anxiety disorder
away before I would take away the BRCA gene (PGD67).
This participant integrated the ideas that cancer is increasingly treatable and survivable, that
social and psychiatric disorders present a greater and more pervasive threat to quality of life
than cancer risk, and that children face a range of challenges that may be debilitating as they
grow into adulthood. Childbearing, she implies, is fraught with anxieties beyond those
specific to a gene mutation that confers susceptibility. She discusses her concerns about
using PGD to select a BRCA mutation-free embryo in relation to her concerns about other
risks:
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“When they’re picking an embryo what if they pick the stupid kid or the ugly kid…
You can’t predict how much money your child’s husband or your child is going to
make. Or whether or not it’s going to struggle in school or not. And to me those are
the bigger things, this is just one little blip” (PGD067).
Comparing cancer to physical attractiveness and intellectual prowess may seem discordant,
yet this participant presents a set of social considerations beyond a parent’s control that
could threaten a future child’s happiness and wellbeing, and shape both the experience of
parenting and of the child’s social and professional prospects. This participant gives voice to
the range of ‘genetic’, or ‘embodied’ traits that may shape the ebb and flow of daily life
(Geelen, Van Hoyweghen & Hortsman, 2011), This life includes provisions not only for a
future child’s physical health, but for their social and emotional health as well. As
prospective parents consider the full range of risks a child might face, the BRCA1/2 gene
mutation may not be only one of many considerations.
“He’s a mini me”: Nature/Nurture Revisited
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A small number of participants were actively seeking or had pursued adoption after attempts
at a conventional pregnancy had failed. Each of these participants prized parenting above
continued attempts at a genetic link to a child. Consideration of adoptions pushed them to
wonder about the extent to which traits are nurtured or inherited, and the meaning of having,
or not having, a genetic link with one’s child. A male participant whose wife conceived
while they were in the process of adopting shared of his son:
Yeah, he’s a complete wise ass just like I was. He’s a mini me. Would my son if he
was an adopted Korean baby look like me? No. But would he have acted like me,
would he have picked up on my traits, would he have had the same sense of humor?
I don’t know about the whole nature versus nurture thing but you know I’d like to
think I would have felt as close to an adopted baby as I did a biological baby
(PGD090).
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This participant spent time emotionally invested in the possibilities of parenting both a
biological and an adopted child. In his biologically related son he sees aspects of his own
character and identifies with him powerfully around those traits (‘he’s a mini me’). Yet, he
distinguishes a desire for children to inherit certain qualities from the love and care a parent
feels for a child regardless of their genetic kinship. Although parents may fantasize about a
child looking, sounding, or thinking like them, this participant alludes to the notion that the
parent/child relationship is not defined by shared genetics but rather by experience and
emotion.
A single female participant recovering from breast cancer and multiple breast surgeries
consulted with one of her fertility specialists and learned that her chance of conceiving a
viable embryo, even with donor gametes, was low. She decided to pursue adoption only to
learn that her cancer diagnosis would likely prevent her from adopting internationally. She
addressed the core nature/nurture debate as she discussed her curiosity about her soon-to-be
privately and domestically adopted son:

NIH-PA Author Manuscript

You might get your overall constitution from your genes, which then has you strong
or weak. I have a very strong constitution…very grounded, logical. So it will be
interesting because I’m going to give that to my child. It will be interesting if he
will have that, too…I talked to this young lady I’m adopting from and she does not
have that. She has quite the opposite. But it’s hard to tell if it’s from her
environment or if it’s from her genes (PGD091).
Although this participant says she believes one’s core self grows from one’s genetic
material, she also alludes to her perception that the environment within which an individual
is raised has an impact on the development of character. She discusses ‘giving’ her adopted
son a stronger constitution than the one offered by his birth mother, yet she is unsure about
whether the birth mother’s life circumstances or her genetic blueprints shaped her character.
“It’s half their child”: Negotiating Family Planning with Partners
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Interwoven with participant beliefs about the nature of a BRCA1/2 mutation and the
importance of maintaining genetic lineage were beliefs about how (and whether) non-carrier
partners should be involved in reproductive planning. Findings were mixed, and differences
in opinion about partner participation may have been tied to variations in understanding
cancer risk and perceptions of severity.
A prime theme addressed the dual responsibility for BRCA1/2 mutation-positive women to
manage physical and emotional aspects of both pregnancy and cancer risk. A participant
planning a conventional pregnancy with her husband stated: “It’s your child together but yet
it′s your body…plus I′m the one with the gene. If anyone has strong feelings about this it’s
me” (PGD02). Other married women, like this one, did not feel the full weight of
reproductive decision-making, describing egalitarian discussion with her partner about the
use of PGD. She shared:
Being partners we’d want to come to some kind of compromise as to how we want
to go along with having our kids and what have you, and what we want to transfer
or not transfer…for me everything is a discussion with my husband (PGD074).
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Family planning negotiations were ongoing (or anticipated) in the context of an established
union.
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Yet, even when coupled participants saw a shared process, for some the ultimate
responsibility for reproductive decision making lay with the woman, whether or not they
were mutation-positive. One participant discussed the interplay between her interest in an
egalitarian process and her ownership of the physical burdens of both pregnancy and cancer
risk.
I mean we’ve talked about it and I think we’re kind of on the same page.
Technically it’s ultimately my decision because it’s my body, but at the same time
it’s our family… I think it’s good to have somebody who’s supportive of what we
have to do (PGD085).
The following participant articulated this differently. She stated:
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Even though it’s half their child I think they get much too much say in these things.
Until they can actually be more than a sperm donor in something like IVF he
certainly can have input. But if I say no what I say has to hold. I should listen to
him and hear him out, but ultimately I think I should have like 51% vote (PGD52).
Women who were not in committed relationships discussed attitudes about a hypothetical
partner’s participation in reproductive decision-making. A single participant shared her
beliefs about marriage and negotiating uptake of assisted reproductive technologies: “In my
ideal marriage it would be an equal process…my belief is most of the time the people we
marry are people who share similar views to your own. So, ideally we would be on the same
page” (PGD08). Another young, single participant stated simply: “Having a baby is 50%
him, 50% me, so I think definitely he should be fully involved” (PGD06).
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The small subset of mutation-positive male participants warranted their own analysis. Male
carriers concurred that, even though they carried the BRCA1/2 mutation, they had ‘49%’ of
the power over reproductive decisions compared to their non-carrier wives. Several
unrelated male and female participants indicated that men have 49% of the vote, while
women have 51%. Participants were not asked to quantify power differentials during
interviews; they offered these numbers spontaneously. The fact that this split centers around
50% alludes to equity. Yet, as one female participant said when asked to qualify these
numbers, “You only need 51%.”
For these men, family planning decisions involved considerable participation by non-carrier
wives, as was evident in the couple interviewed together. A married, mutation-positive male
whose wife, mother, and sister were diagnosed with breast cancer within a few years of each
other discussed his views on balancing ownership of the mutation with reproduction:
I forget that it’s me and not her. It’s just like ‘we,’ you know? I almost feel like it’s
more of a ‘her’ thing, because as much as the mutation is mine, the pregnancy is
hers, and one we have some control over, the other we don’t. So the one that we
have control over, the pregnancy, the nature of it and how it’s started, is hers”
(PGD092).
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A married male participant whose wife suffered several miscarriages that he described as
“worse than cancer,” when asked how much sway he had over reproductive decisions,
answered simply: “Forty nine per cent” (PGD090). Another husband struggled with the
need for his non-carrier wife to endure invasive procedures to achieve a pregnancy with a
BRCA mutation-free baby as a result of his BRCA carrier status. He shared:
I guess the whole pregnancy thing, I just look at it as you know it’s the wife not the
husband…I mean it’s her body. Again, I mean it’s our child and our pregnancy
together, but I do feel like she has 51% of the vote. But, again, when I tell her that I
know I feel a little bit guilty saying, “Oh, you figure it out.” … The fact that it’s me
who’s positive, not my wife, doesn’t even a little bit give me any sort of pride of
place in the decision making process (PGD098).
A third young husband recognized his interest in conceiving a BRCA mutation-negative
baby was secondary to his wife’s lack of interest in (or desire to avoid) PGD. He says:
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It’s a lot easier for me to say, “Hey, I think it’s a good idea.” When it really isn’t
affecting me nearly…I mentioned it to [wife and mother], and neither were too hot
on it. So I was like, I guess I’m wrong. I really haven’t brought it up again
(PGD082).
Summary
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Participants discussed the experience of reconciling a BRCA1/2 mutation with the desirable
and undesirable traits they had to offer a child, whether through genetic inheritance or
through parenting. In thinking about PGD to screen embryos for a BRCA1/2 mutation,
participants thought explicitly about those desirable and undesirable traits their partner
contributed to a future child, including both identifiable and hypothetical risks. As
participants framed the BRCA1/2 mutation as one piece of a comprehensive set of genetic
and social strengths and risks, they attempted to reconcile the random nature of reproduction
with the imperfect, expensive and medically invasive, yet seemingly more certain
technology of PGD. Yet, PGD introduces additional risks into reproduction including the
possibility that a would-be parent might commit a sin of commission by selecting in
something ‘worse’ than increased risk of breast and ovarian cancer while selecting out a
BRCA1/2 mutation. The decision to engage with assisted reproductive technology required
consideration (and for some, rejection) of partner preferences with respect to family
planning and a child’s potential for inherited cancer risk.
Limitations
Participants experienced genetic counseling between 2000-2009, representing a broad time
frame within which recommendations for prevention and opportunities for PGD changed
substantially. As a result, participants had uneven exposure to PGD-related information
during their genetic counseling experiences. To correct for this, we designed the educational
presentation to provide biomedical, psychosocial, and financial information about PGD and
prenatal diagnosis. The tutorial mentions (1) that more individuals diagnosed with cancer are
now surviving, and (2) the possibility for scientific discoveries that might improve early
detection, prevention, and treatment of BRCA-related cancers. While these statements are
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supported by widely available national data sets (Ries, Melbert, Krapcho, et al., 2007), this
information may have skewed participants towards optimistic biases or towards a
biomedical view of reproduction and risk reduction. Alternatively, since PGD is an invasive
and costly option, its introduction may have suggested greater severity of BRCA1/2 cancer
risk than participants were comfortable with and participants may have minimized their own
cancer risk in reaction to perceptions of PGD as a drastic option. Further, one reason for
declining participation in this study was expressed emotional difficulty with the topic, and
many did not cite a specific reason for declining. As a result, it is unclear what other
sampling biases might have been introduced.
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Recruitment was limited to two unique medical environments located in a dynamic, urban,
progressive community serving an affluent and educated demographic. Recruitment did not
approach saturation for non-white groups, and few participants were of lower
socioeconomic status. The under-representation of minority groups in current at-risk clinical
populations, due, in part, to lower uptake of genetic counseling and testing (Thompson et al.,
2002, Halbert et al., 2006) and to the higher incidence of receiving a variant result (Nanda et
al, 2005) poses a limitation to this project. We were unable to reach saturation in interviews
with ethnic minority women and men, whose views might diverge significantly from those
of whites due to differences in spiritual beliefs and cultural and social experiences. Due to
restrictions on chart review instituted by the human subjects review board, we have limited
information about decliners, despite cursory responses about their expressed reason for
declining participation. Finally, our sample was composed of predominantly heterosexual
couples; issues of genetic inheritance may be quite different for same-sex couples already
considering gamete donation and the use of assisted reproductive technology (Mamo, 2007).

DISCUSSION
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Findings from the Human Genome Project suggest, and participants echoed, that we might
all be genetically vulnerable in some way. The BRCA1/2 gene mutation is separate from
many other inherited susceptibilities merely in that we can identify it through genetic
testing. The purpose of pursuing genetic testing is ostensibly to become proactive in
managing inherited cancer risk to prevent disease and to reduce mortality. A primary
concern for patients of reproductive age is the 50% chance of each child inheriting the
deleterious mutation. As repro-genetic technologies become more widely available for adult
onset disorders, and as awareness of their availability grows, pressure to use them may
increase for would-be parents. Partners, extended family, and physicians, as well as notions
about what makes a ‘good patient’ and a ‘good parent’ may exert pressure on BRCA1/2
mutation carriers who experience a sense of obligation not only to protect a future child
from a mutated genetic line (and painful family history), but also to preserve a partner’s
‘clean’ bloodline.
Essentialist Genetics and the Nature/Nurture Debate
Genetic discovery in the last decade has linked specific gene mutations (or combinations of
mutations) to the expression of specific conditions and traits. These links favor a ‘nature’
based view of birth and illness outcomes, privileging the genetic contributions to disease,
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while diminishing the ‘nurture’ components of our social and physical environments and the
complex interplay between genes and these environments (Shakespeare, 1995). As the
nature/nurture debate is revisited from an essentialist perspective, preference for a
biologically related child who is ‘of’ the couple is pitted against social pressure for ablebodied children (Ettorre, 2000), and remains in tension with cultural imperative to birth
healthy children by all means possible (Rapp, 1999, Finker, 2000). Participants balanced
feelings about the BRCA1/2 mutation as evidence of a “damaged” genetic line (Werner-Lin,
2007) with the understanding that this mutation constitutes only one piece of what a child
inherits from each genetically linked parent. The rapidly evolving nature of genetic research
and the likelihood that susceptibility testing will be available in the future for other common
disorders lead participants to view the BRCA1/2 mutation as one risk among potentially
many.
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Social scientists have critiqued scientific and public discourse for essentializing genetics in
the expression of conditions or traits and minimizing context and environments (Finkler,
2005;) and medicalizing kinship and family formation (Finkler, Skrzynia & Evans, 2003)
rather than develop more holistic, comprehensive ecological models (Sluzki, 2007). This
discourse implicitly elevates the genetic link from parent to child above legal or emotional
ties (Strathern, 1995). The Western idealized family form (heterosexual, married couple
with genetically linked children) continues to be prized above other increasingly common
family forms, for example: lesbian couples parenting children related biologically to neither
parent, to one parent, or, in more complicated ways, to both parents, such as when one
partner becomes pregnant with an embryo using the other partner’s egg. The tension
between genetic essentialism and the integration of nature and nurture was evident in
participant interviews. Participants who discussed family formation expressed a preference
for a genetic link to their children. Although participants did not want their children to
inherit the BRCA1/2 mutation, they expressed hopes for their children’s inheritance of other
prized traits and discussed their beliefs about the extent to which these traits are socialized in
the context of family life or are purely inherited (Hortsman & Finkler, 2011; Richards,
1996).
Couple Dynamics, Sex, and Gender
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Individuals with disparate exposure to family illness and loss may bring divergent opinions
about genetic inheritance and reproduction to family planning endeavors. This may create
tension for couples with significantly different medical family histories and may have
implications for therapeutic work and future research with couples and families (McDaniel,
2005) considering genetic counseling (Hoskins, Roy, Peters, Loud & Greene, 2008) or the
use of genetically enhanced assisted-reproductive technologies. Participants in this
investigation struggled to varying degrees with when and how to involve non-BRCA
carrying partners in decisions about the use of PGD, especially when perspectives about
inheritance, adoption, and illness diverged. Some participants coupled reproductive and
cancer risk management decisions, proceeding on their own terms with minimal input and
influence from their partners. Others approached these issues separately, addressing family
planning as a joint decision about the family’s future and addressing cancer risk
management individually as unique to the woman’s health. Individuals and couples
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negotiating these issues might be counseled to approach reproductive decisions in a
thoughtful and deliberate manner, and to identify whether and how to include a real or future
partner’s illness histories, preferences, and beliefs into decision processes.
Male mutation carriers discussed their unique role vis-à-vis their mutation-negative wives.
The confluence of lower risk estimates and their inability to be ‘more than a sperm donor’
(PGD052) in reproduction shaped a perspective expressed by the few men we interviewed:
the BRCA1/2 mutation was a shared vulnerability in their marriage. Yet pervasive in the
sample, among both women and men, was the belief that, despite whatever negotiations or
conflicts arise between partners, women have the ultimate control over when and how they
care for their bodies and pursue family planning. This perspective may be specific to our
sample: educated, Westernized, affluent, liberal individuals seeking care at a highly
respected medical institution.
Implications for Future Research
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Research is needed to investigate the experiences of BRCA1/2 mutation-positive men.
Existing cross sectional survey data together (Menon, Harper, Sharma, et al., 2007; Quinn,
et al., 2010), and the few in-depth interviews presented here identify key issues faced by
men from families affected by hereditary breast and ovarian cancer, yet these data remain
insufficient. Due to the widely disparate BRCA-related risk estimates, lower uptake of
genetic testing, and the lack of screening protocols or preventive measures, male carriers are
sorely underrepresented in the literature (Moynihan, 2011). As one male participant told us,
the genetic counselor framed his carrier status as an issue for his (as-of-yet nonexistent)
daughters, not for him. This perspective may marginalize men in both family and medical
settings and deny them needed support (Maughan, Heyman & Matthews, 2002) as their
mutation status disables men from traditional notions of familial paternalism, limiting their
ability to protect children from dangers.
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BRCA genetic counseling frequently pushes reproductive decisions earlier in the life cycle.
As a result, research should address the critical experiences of women considering family
planning and the use of repro-genetic technology before they otherwise would and,
potentially, outside the context of an established partnership. Finally, this particular arm of
the study interviewed only one couple. Future research should attempt prospective designs
by recruiting individuals and couples actively engaged in family planning. Exploratory
research should approach couples as the primary unit of study (Kayser, Watson & Andrade,
2007; Lammens, Bleiker, Aaronson, et al., 2009) to identify points of congruence and
difference and how differences are actively negotiated.
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Table 1

NIH-PA Author Manuscript

Excerpted Interview Guide
Interview Guide
1

Tell me about your experience of cancer in your family.

2

How do you feel about the screening and prevention options for BRCA mutation carriers?

Personal Plans for Childbearing
3

Did thinking about your cancer risk affect your plans for children before genetic testing?

4

Did thinking about your family’s history with cancer impact your thoughts or plans to have children? If so, how?

5

How, if at all, did your thoughts or plans change after genetic testing?

6

What challenges have you faced carrying a BRCA and (thinking about) planning a family? Have you spoken with your
family/partner about these challenges? Have you spoken with your genetic counselor or physician about these challenges?

7

How do you feel about your child’s risk for inheriting a BRCA mutation?

8

How have you managed your feelings about the possibility of your child inheriting a BRCA mutation? Have you discussed
these feelings with your partner? With your family?

9

Have you or are you considering using PGD to prevent transmission of the BRCA gene mutation to your child? Tell me
about any other reproductive options you considered.

Pre-implantation Genetic Diagnosis (PGD)

NIH-PA Author Manuscript

As a reminder, PGD is the identification of a condition in an embryo before it is transferred to the uterus. PGD requires that couples have
in vitro fertilization treatment with an additional genetic testing phase.
10

Tell me about any experience you have had with Assisted Reproductive Technologies, such as IVF.

11

What are your feelings and attitudes about the possibility of using PGD to prevent transmission of a BRCA mutation?

Genetic Counseling about PGD and PND
12

How, if at all, do you think genetic counselors should talk with patients about the option of PGD? About the option of
prenatal diagnosis?
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